Key Takeaway: Nurix is dedicated to developing innovative therapies by leveraging novel scientific insights. The company aims to enhance its portfolio of assets to effectively combat cancer and autoimmune diseases. Their focus on protein degradation resources highlights their commitment to advancing targeted protein modulation.
Price reaction · baseline $25.2 (2024-08-30 close) · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-1.3%
Market Sentiment Analysis
POSITIVE FACTORS
Nurix is focused on translating scientific insights into therapies.
The company is advancing a multi-modal portfolio of assets.
There is a commitment to addressing cancer and autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is Nurix focused on?
Nurix is focused on translating scientific insights into breakthrough therapies.
What diseases is Nurix targeting?
Nurix aims to combat cancer and autoimmune diseases.
What type of portfolio does Nurix have?
Nurix has a multi-modal portfolio of wholly owned and partnered assets.